



NOTICE

Notice No.	20260602-25
Notice Date	02 Jun 2026
Category	Trading
Segment	Equity
Department	Listing Business Relationship
Subject	Opening of Offer to Buy – Acquisition Window (Buyback) For Zydus Lifesciences Limited
Attachments	Letter of Offer

Trading Members and Custodians are requested to note that Securities Exchange Board of India (SEBI) has issued Mechanism for acquisition of shares through Stock Exchange pursuant to Tender-Offers under Takeover, Buy Back and De-listing vide its circular no. CIR/CFD/POLICYCELL/1/2015 dated April 13, 2015, and no. CFD/DCR2/CIR/P/2016/131 dated Dec 09, 2016. The Exchange vide its notice no. 20170210-16 dated Feb 10, 2017, 20190424-35 dated April 24, 2019, and 20200528-32 dated 28 May 2020, 20201102-43 dated 02 Nov 2020, 20210825-62 dated Aug 25, 2021 has issued Revised Guidelines of Mechanism for acquisition of shares through Stock Exchange pursuant to Tender-Offers under Takeovers, BuyBack and Delisting.

All Market Participants are hereby informed that **Zydus Lifesciences Limited (“The Company”)** proposes to Buyback up to **87,30,158 (Eighty Seven Lakh Thirty Thousand One Hundred and Fifty Eight) Fully Paid-up Equity Shares** of the Company, having face value of INR 1/- (Indian Rupee One Only) each (“Equity Shares”), representing 0.87% of the Total Number of Equity Shares in the paid-up share capital of the company, from the Equity Shareholders/ Beneficial owners of Equity shares of the Company as on May 29, 2026 (“Record Date”) on a proportionate basis, through the “Tender Offer” route at a price of **INR1,260/- (Indian Rupees One Thousand Two Hundred and Sixty Only) per equity share**, payable in cash, for an aggregate amount not exceeding INR **1100,00,00,000/- (Indian Rupees One Thousand One Hundred Crore Only) excluding transaction costs**. The Buyback Size represents 5.16% and 3.84% of the aggregate of the total paid-up equity share capital and free reserves of the Company as per the latest audited standalone and consolidated financial statements of the Company as at March 31, 2026, respectively, and is within the statutory limit of 10% of the aggregate of the total paid-up equity share capital and free reserves of the Company, based on both standalone and consolidated financial statements of the Company, under the board approval route as per Section 68 and other applicable provisions of the Companies Act and Regulation 5 and other applicable provisions of the Buyback Regulations, **from Thursday, June 4, 2026, to Wednesday, June 10, 2026.**

Letter of Offer is herewith attached for your perusal.

Market participants are further requested to note that this offer will be as per the Revised Guidelines of SEBI circular no. CFD/DCR2/CIR/P/2016/131 dated Dec 09, 2016 and Exchange notice no. 20170210-16 dated Feb 10, 2017 and 20190424-35 dated April 24, 2019 along with the details of this Offer to Buy would be available on BSE Website – www.bseindia.com.

Mangesh Tayde

Vice President

Listing Business Relationship

June 02, 2026